HER2 is a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family. Amplification or over-expression of this oncogene has been shown to play an important role in the development and progression of certain aggressive types of breast cancer. In recent years this protein has become an important biomarker and target of therapy for many breast cancer patients. Herceptin (Trastuzumab) is a monoclonal antibody used to treat breast cancer. Trastuzumab antibody-drug conjugates (ADCs) are a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the cytotoxic effects of chemotherapy drugs.

protein – protein | antibody | ADCs | MOX-P-117